Oxford BioDynamics' Bartu Ahiska on breakthrough CFS test

Proactive - Interviews for investors

Oxford BioDynamics PLC (AIM:OBD, OTC:OXBOF) senior director of commercial development & marketing comms, Bartu Ahiska, talked with Proactive's Stephen Gunnion about the company’s breakthrough diagnostic blood test for chronic fatigue syndrome (CFS), also known as ME. Ahiska said this was the first time a test had been able to detect chronic fatigue syndrome from blood with 96% accuracy, marking a significant milestone for the company and offering hope for patients globally. “This is a serious illness with millions of people waiting for a reliable diagnosis all around the globe,” he said. The test, which also demonstrated 92% sensitivity and 98% specificity, is based on Oxford BioDynamics’ EpiSwitch platform. Unlike fixed DNA tests, EpiSwitch examines how DNA folds and switches on or off in 3D, which enables it to detect disease-related changes not present at birth. Ahiska said the test still needs further validation and clinical utility studies before it can be deployed. He added that the company is now looking to co-develop or license the test with a partner, aiming for deployment in OBD’s or partner labs. He also confirmed that the EpiSwitch platform and associated IP are protected and scalable, with potential for global rollout. Furthermore, the company sees potential in adapting the test to address long Covid, given the overlap in biological pathways. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and enable notifications for future content. #OxfordBioDynamics #ChronicFatigue #CFS #MECFS #BloodTest #Biotech #HealthcareInnovation #EpiSwitch #PrecisionMedicine #LongCovid #DiagnosticTesting #MedicalResearch #ProactiveInvestors